COVID-19 vaccines and blood glucose control: Friend or foe?

References

• Kim JJ. The role of cost-effectiveness in US vaccination policy. N Engl J Med. 2011;365(19):1760–7. doi:10.1056/NEJMp1110539.
   PubMed Web of Science ®Google Scholar
• Meng H, Mao J, Ye Q. Booster vaccination strategy: necessity, immunization objectives, immunization strategy, and safety. J Med Virol. 2022;94(6):2369–75. doi:10.1002/jmv.27590.
   PubMed Web of Science ®Google Scholar
• Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022;322(1):C1–c11. doi:10.1152/ajpcell.00375.2021.
   PubMed Web of Science ®Google Scholar
• Mirza SA, Sheikh AAE, Barbera M, Ijaz Z, Javaid MA, Shekhar R, Pal S, Sheikh AB. COVID-19 and the endocrine system: a review of the current information and misinformation. Infect Dis Rep. 2022;14(2):184–97. doi:10.3390/idr14020023.
   PubMed Web of Science ®Google Scholar
• Lisco G, De Tullio A, Stragapede A, Solimando AG, Albanese F, Capobianco M, Giagulli VA, Guastamacchia E, De Pergola G, Vacca A. COVID-19 and the endocrine system: a comprehensive review on the theme. J Clin Med. 2021;10(13):2920. doi:10.3390/jcm10132920.
   PubMed Web of Science ®Google Scholar
• Lazartigues E, Qadir MMF, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2’s reliance on ACE2. Endocrinology. 2020;161(9). doi:10.1210/endocr/bqaa108.
   PubMed Web of Science ®Google Scholar
• Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after COVID-19. Diabetologia. 2022;65(6):949–54. doi:10.1007/s00125-022-05670-0.
   PubMed Web of Science ®Google Scholar
• Choi JH, Kim KM, Song K, Seo GH. Risk for newly diagnosed type 2 diabetes mellitus after COVID-19 among Korean adults: a nationwide matched cohort study. Endocrinol Metab (Seoul). 2023;38(2):245–52. doi:10.3803/EnM.2023.1662.
   PubMedGoogle Scholar
• Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582. doi:10.3389/fimmu.2020.01582.
   PubMed Web of Science ®Google Scholar
• Joshi SR, Shaw AC, Quagliarello VJ. Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine. Yale J Biol Med. 2009;82:143–51.
   PubMedGoogle Scholar
• Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906–12. doi:10.1056/NEJM199912163412507.
   PubMed Web of Science ®Google Scholar
• Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GEHM. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281–8. doi:10.1086/431587.
   PubMed Web of Science ®Google Scholar
• Fang M, Ishigami J, Echouffo-Tcheugui JB, Lutsey PL, Pankow JS, Selvin E. Diabetes and the risk of hospitalisation for infection: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2021;64(11):2458–65. doi:10.1007/s00125-021-05522-3.
   PubMed Web of Science ®Google Scholar
• Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi E, Mazziotti G, Lania AG. Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic hospital in Lombardy, Italy. Diabetes Care. 2020;43(12):3042–9. doi:10.2337/dc20-1340.
   PubMed Web of Science ®Google Scholar
• Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro F, Isidori AM, Pivonello R, Salonia A, Sforza A, Maggi M. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis. Rev Endocr Metab Disord. 2021;22(2):275–96. doi:10.1007/s11154-021-09630-8.
   PubMed Web of Science ®Google Scholar
• Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes. 2022;41(1):4–31. doi:10.2337/cd23-as01.
   PubMedGoogle Scholar
• Zhao Y, Wu X. Influence of COVID-19 vaccines on endocrine system. Endocrine. 2022;78(2):241–6. doi:10.1007/s12020-022-03119-3.
   PubMed Web of Science ®Google Scholar
• Almasri L, Holtzclaw BJ. Assessing vaccine protection for older adults with diabetes: a systematic review. West J Nurs Res. 2022;44(6):582–97. doi:10.1177/01939459211005710.
   PubMed Web of Science ®Google Scholar
• Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, Indenbaum V, Mandelboim M, Doolman R, Amit S. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999–1009. doi:10.1016/S2213-2600(21)00220-4.
   PubMed Web of Science ®Google Scholar
• Mitsunaga T, Ohtaki Y, Seki Y, Yoshioka M, Mori H, Suzuka M, Mashiko S, Takeda S, Mashiko K. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021;9:e12316. doi:10.7717/peerj.12316.
   PubMed Web of Science ®Google Scholar
• Virgilio E, Trevisan C, Abbatecola A, Malara A, Palmieri A, Fedele G, Stefanelli P, Leone P, Schiavoni I, Maggi S. Diabetes affects antibody response to SARS-CoV-2 vaccination in older residents of long-term care facilities: data from the GeroCovid vax study. Diabetes Care. 2022;45(12):2935–42. doi:10.2337/dc22-1255.
   PubMed Web of Science ®Google Scholar
• Ali H, Alterki A, Sindhu S, Alahmad B, Hammad M, Al-Sabah S, Alghounaim M, Jamal MH, Aldei A, Mairza MJ. Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front Immunol. 2021;12:752233. doi:10.3389/fimmu.2021.752233.
   PubMed Web of Science ®Google Scholar
• Marfella R, D’Onofrio N, Sardu C, Scisciola L, Maggi P, Coppola N, Romano C, Messina V, Turriziani F, Siniscalchi M. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes Metab. 2022;24(1):160–5. doi:10.1111/dom.14547.
   PubMed Web of Science ®Google Scholar
• Papadokostaki E, Tentolouris A, Anastasiou IA, Psichogiou M, Iliaki E, Eleftheriadou I, Hatzakis A, Tentolouris N. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in people with diabetes: a prospective observational study. Vaccines. 2022;10(3):382. doi:10.3390/vaccines10030382.
   Web of Science ®Google Scholar
• Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, Kojzar H, Kleinhappl B, Pferschy PN, Mader JK. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022;24(5):849–58. doi:10.1111/dom.14643.
   PubMed Web of Science ®Google Scholar
• Emeksiz HC, Hepokur MN, Şahin SE, Şirvan BN, Çiçek B, Önder A, Yıldız M, Aksakal DK, Bideci A, Ovalı HF. Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes. Front Pediatr. 2023;11:1191706. doi:10.3389/fped.2023.1191706.
   PubMed Web of Science ®Google Scholar
• Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4(2):148–58. doi:10.1016/S2213-8587(15)00379-4.
   PubMed Web of Science ®Google Scholar
• Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044. doi:10.1016/j.molmet.2020.101044.
   PubMed Web of Science ®Google Scholar
• Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, Zhao Y. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl). 2012;90(2):175–86. doi:10.1007/s00109-011-0816-5.
   PubMed Web of Science ®Google Scholar
• Xia C, Rao X, Zhong J. Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. J Diabetes Res. 2017;2017:1–6. doi:10.1155/2017/6494795.
   Web of Science ®Google Scholar
• DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, Markham D, Strissel KJ, Watkins AA, Zhu M. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci USA. 2013;110(13):5133–8. doi:10.1073/pnas.1215840110.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park K, Lee SB, Kang S, Park JS, Ahn CW, Nam, JS Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. J Diabetes Investig. 2019;10(5):1223–8. doi:10.1111/jdi.13002.
   PubMed Web of Science ®Google Scholar
• Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15(2):256–60. doi:10.2337/diacare.15.2.256.
   PubMed Web of Science ®Google Scholar
• Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med. 1997;14(1):29–34. doi:10.1002/(SICI)1096-9136(199701)14:1<29:AID-DIA300>3.0.CO;2-V.
   PubMed Web of Science ®Google Scholar
• Huang J, Xiao Y, Zheng P, Zhou W, Wang Y, Huang G, Xu A, Zhou Z. Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes Metab Res Rev. 2019;35(1):e3064. doi:10.1002/dmrr.3064.
   PubMed Web of Science ®Google Scholar
• Lecube A, Pachón G, Petriz J, Hernández C, Simó R, Sesti G. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLOS ONE. 2011;6(8):e23366. doi:10.1371/journal.pone.0023366.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Piperi C, Ziakas PD, Apostolopoulos NV, Makrilakis K, Syriou V, Diamanti-Kandarakis E, Kaltsas G, Kalofoutis A. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol. 2008;28(4):314–21. doi:10.1007/s10875-007-9164-1.
   PubMed Web of Science ®Google Scholar
• Morris G, Gevezova M, Sarafian V, Maes M. Redox regulation of the immune response. Cell Mol Immunol. 2022;19(10):1079–101. doi:10.1038/s41423-022-00902-0.
   PubMed Web of Science ®Google Scholar
• Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci. 2013;14(11):21525–50. doi:10.3390/ijms141121525.
   PubMed Web of Science ®Google Scholar
• Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clin Mol Allergy. 2017;15(1):21. doi:10.1186/s12948-017-0077-0.
   PubMedGoogle Scholar
• Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, Solana R. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50–5. doi:10.1016/j.maturitas.2015.05.004.
   PubMed Web of Science ®Google Scholar
• Dorrell L, Hassan I, Marshall S, Chakraverty P. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS. 1997;8(12):776–9. doi:10.1258/0956462971919264.
   PubMed Web of Science ®Google Scholar
• Feery BJ, Hartman LJ, Hampson AW, Proietto J. Influenza immunization in adults with diabetes mellitus. Diabetes Care. 1983;6(5):475–8. doi:10.2337/diacare.6.5.475.
   PubMed Web of Science ®Google Scholar
• Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939–49. doi:10.1016/S1473-3099(21)00224-3.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–2. doi:10.1001/jama.2021.1967.
   PubMed Web of Science ®Google Scholar
• Goddard K, Lewis N, Fireman B, Weintraub E, Shimabukuro T, Zerbo O, Boyce TG, Oster ME, Hanson KE, Donahue JG. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022;40(35):5153–9. doi:10.1016/j.vaccine.2022.07.007.
   PubMed Web of Science ®Google Scholar
• See I, Lale A, Marquez P, Streiff MB, Wheeler AP, Tepper NK, Woo EJ, Broder KR, Edwards KM, Gallego R. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 Vaccination—United States, December 2020 to August 2021. Ann Intern Med. 2022;175(4):513–22. doi:10.7326/M21-4502.
   PubMed Web of Science ®Google Scholar
• Edwards AE, Vathenen R, Henson SM, Finer S, Gunganah K. Acute hyperglycaemic crisis after vaccination against COVID-19: a case series. Diabet Med. 2021;38(11):e14631. doi:10.1111/dme.14631.
   PubMed Web of Science ®Google Scholar
• Zilbermint M, Demidowich AP. Severe diabetic ketoacidosis after the second dose of mRNA-1273 COVID-19 vaccine. J Diabetes Sci Technol. 2022;16(1):248–9. doi:10.1177/19322968211043552.
   PubMedGoogle Scholar
• Lee HJ, Sajan A, Tomer Y. Hyperglycemic emergencies associated with COVID-19 vaccination: a case series and discussion. J Endocr Soc. 2021;5(11):bvab141. doi:10.1210/jendso/bvab141.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Itoh A, Watanabe Y, Nakajima Y, Saisho Y, Irie J, Meguro S, Itoh H. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Invest. 2022;13(6):1105–8. doi:10.1111/jdi.13757.
   PubMed Web of Science ®Google Scholar
• Aydoğan B, Ünlütürk U, Cesur M. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination. Endocrine. 2022;78(1):42–6. doi:10.1007/s12020-022-03130-8.
   PubMed Web of Science ®Google Scholar
• Tang X, He B, Liu Z, Zhou Z, Li X. Fulminant type 1 diabetes after COVID-19 vaccination. Diabetes Metab. 2022;48(2):101324. doi:10.1016/j.diabet.2022.101324.
   PubMed Web of Science ®Google Scholar
• Piccini B, Pessina B, Pezzoli F, Casalini E, Toni S. COVID-19 vaccination in adolescents and young adults with type 1 diabetes: glycemic control and side effects. Pediatr Diabetes. 2022;23(4):469–72. doi:10.1111/pedi.13326.
   PubMed Web of Science ®Google Scholar
• Gouda N, Dimitriadou M, Sotiriou G, Christoforidis A. The impact of COVID-19 vaccination on glycaemic control in children and adolescents with type 1 diabetes mellitus on continuous glucose monitoring. Acta Diabetol. 2022;59(12):1609–14. doi:10.1007/s00592-022-01968-y.
   PubMed Web of Science ®Google Scholar
• D’Onofrio L, Coraggio L, Zurru A, Carlone A, Mignogna C, Moretti C, Maddaloni, E, Buzzetti, R. Short-term safety profile of sars-Cov2 vaccination on glucose control: continuous glucose monitoring data in people with autoimmune diabetes. Diabetes Res Clin Pract. 2021;179:109022. doi:10.1016/j.diabres.2021.109022.
   PubMed Web of Science ®Google Scholar
• D’Addio F, Sabiu G, Usuelli V, Assi E, Abdelsalam A, Maestroni A, Seelam AJ, Ben Nasr M, Loretelli C, Mileto D. Immunogenicity and Safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes. Diabetes. 2022;71(8):1800–6. doi:10.2337/db22-0053.
   PubMed Web of Science ®Google Scholar
• Lu D, Gao Y, Qi X, Li A, Zhang J. The COVID-19 vaccination hesitancy among Chinese individuals with diabetes and the impact on glycemic control of vaccination: a questionnaire study. BMC Endocr Disord. 2022;22(1):329. doi:10.1186/s12902-022-01201-5.
   PubMed Web of Science ®Google Scholar
• Aberer F, Moser O, Aziz F, Sourij C, Ziko H, Lenz J, Abbas F, Obermayer AM, Kojzar H, Pferschy PN. Impact of COVID-19 vaccination on glycemia in individuals with type 1 and type 2 diabetes: substudy of the COVAC-DM study. Diabetes Care. 2022;45(2):24–6. doi:10.2337/dc21-1563.
   Web of Science ®Google Scholar
• Heald AH, Stedman M, Horne L, Rea R, Whyte M, Gibson JM, Anderson SG, Ollier W. The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes. Diabet Med. 2022;39(4):e14774. doi:10.1111/dme.14774.
   PubMed Web of Science ®Google Scholar
• Heald AH, Rea R, Horne L, Metters A, Steele T, Leivesley K, Whyte MB, Stedman M, Ollier W. Analysis of continuous glucose tracking data in people with type 1 diabetes after COVID-19 vaccination reveals unexpected link between immune and metabolic response, augmented by adjunctive oral medication. Int J Clin Pract. 2021;75(12):e14714. doi:10.1111/ijcp.14714.
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Vitale V, Cosentino C, Cresci B, Pala L, Pieri M, Yannas D, Vannucci M, Zago E, Romani A. Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS). Acta Diabetol. 2022;59(3):435–8. doi:10.1007/s00592-021-01837-0.
   PubMed Web of Science ®Google Scholar
• di Mauro G, Mascolo A, Longo M, Maiorino MI, Scappaticcio L, Bellastella G, Esposito K, Capuano A. European safety analysis of mRNA and viral vector COVID-19 vaccines on glucose metabolism events. Pharmaceuticals (Basel). 2022;15(6):677. doi:10.3390/ph15060677.
   PubMedGoogle Scholar
• Lin CW, Hung SY, Chen IW. A study of glycemic perturbations following two doses of COVID-19 vaccination for patients with diabetes: the impacts of vaccine type and anti-diabetes drugs. Diabetol Metab Syndr. 2023;15(1):81. doi:10.1186/s13098-023-01059-0.
   PubMed Web of Science ®Google Scholar
• Karavanaki K, Rodolaki K, Soldatou A, Karanasios S, Kakleas K. Covid-19 infection in children and adolescents and its association with type 1 diabetes mellitus (T1d) presentation and management. Endocrine. 2023;80(2):237–52. doi:10.1007/s12020-022-03266-7.
   PubMed Web of Science ®Google Scholar
• Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, Weil T, Koepke L, Bozzo CP, Read C. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149–65. doi:10.1038/s42255-021-00347-1.
   PubMedGoogle Scholar
• Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, Overbergh L, Gysemans C, Colli ML, Marchetti P. SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature. Front Endocrinol (Lausanne). 2020;11:596898. doi:10.3389/fendo.2020.596898.
   PubMed Web of Science ®Google Scholar
• Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review. Endocrinology. 2022;163(1). doi:10.1210/endocr/bqab203.
   Web of Science ®Google Scholar
• Boskabadi SJ, Ala S, Heydari F, Ebrahimi M, Jamnani AN. Acute pancreatitis following COVID-19 vaccine: Aa case report and brief literature review. Heliyon. 2023;9(1):e12914. doi:10.1016/j.heliyon.2023.e12914.
   PubMed Web of Science ®Google Scholar
• Cieślewicz A, Dudek M, Krela-Kaźmierczak I, Jabłecka A, Lesiak M, Korzeniowska K. Pancreatic injury after COVID-19 vaccine—a case report. Vaccines. 2021;9(6):576. doi:10.3390/vaccines9060576.
   Web of Science ®Google Scholar
• Salvucci F, Codella R, Coppola A, Zacchei I, Grassi G, Anti ML, Nitisoara N, Luzi L, Gazzaruso C. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. Front Cardiovasc Med. 2023;10:1202696. doi:10.3389/fcvm.2023.1202696.
   PubMed Web of Science ®Google Scholar
• Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. doi:10.1038/s41574-020-00435-4.
   PubMed Web of Science ®Google Scholar
• Shi J, Fan J, Su Q, Yang Z. Cytokines and abnormal glucose and lipid metabolism. Front Endocrinol (Lausanne). 2019;10:703. doi:10.3389/fendo.2019.00703.
   PubMed Web of Science ®Google Scholar
• Murata K, Nakao N, Ishiuchi N, Fukui T, Katsuya N, Fukumoto W, Oka H, Yoshikawa N, Nagao T, Namera A. Four cases of cytokine storm after COVID-19 vaccination: case report. Front Immunol. 2022;13:967226. doi:10.3389/fimmu.2022.967226.
   PubMed Web of Science ®Google Scholar
• Samuel SM, Varghese E, Triggle CR, Büsselberg D. COVID-19 vaccines and hyperglycemia—is there a need for postvaccination surveillance? Vaccines. 2022;10(3):454. doi:10.3390/vaccines10030454.
   Web of Science ®Google Scholar
• Lugar M, Eugster A, Achenbach P, von Dem Berge T, Berner R, Besser REJ, Casteels K, Elding Larsson H, Gemulla G, Kordonouri O. SARS-CoV-2 infection and development of islet autoimmunity in early childhood. JAMA. 2023;330(12):1151–60. doi:10.1001/jama.2023.16348.
   PubMed Web of Science ®Google Scholar
• Khunti K, Valabhji J, Misra S. Diabetes and the COVID-19 pandemic. Diabetologia. 2023;66(2):255–66. doi:10.1007/s00125-022-05833-z.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, Pan H-F. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386–401. doi:10.1111/imm.13443.
   PubMed Web of Science ®Google Scholar
• Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125:102738. doi:10.1016/j.jaut.2021.102738.
   PubMed Web of Science ®Google Scholar